PRECAUTIONS O
General O
Discontinuation O
Symptoms O
There O
have O
been O
reports O
of O
adverse B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
the I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
REMERON I-OSE_Labeled_AE
( O
mirtazapine O
) O
Tablets O
( O
particularly O
when O
abrupt O
) O
, O
including O
but O
not O
limited O
to O
the O
following O
: O
dizziness B-NonOSE_AE
, O
abnormal B-NonOSE_AE
dreams I-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
including O
paresthesia B-NonOSE_AE
and O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
agitation B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
tremor B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
and O
sweating B-NonOSE_AE
, O
or O
other O
symptoms O
which O
may O
be O
of O
clinical O
significance O
. O

The O
majority O
of O
the O
reported O
cases O
are O
mild O
and O
self-limiting O
. O

Even O
though O
these O
have O
been O
reported O
as O
adverse O
reactions O
, O
it O
should O
be O
realized O
that O
these O
symptoms O
may O
be O
related O
to O
underlying O
disease O
. O

Patients O
currently O
taking O
REMERON O
should O
NOT O
discontinue O
treatment O
abruptly O
, O
due O
to O
risk O
of O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

At O
the O
time O
that O
a O
medical O
decision O
is O
made O
to O
discontinue O
treatment O
with O
REMERON O
, O
a O
gradual O
reduction O
in O
the O
dose O
, O
rather O
than O
an O
abrupt O
cessation O
, O
is O
recommended O
. O

Akathisia/Psychomotor O
Restlessness O
The O
use O
of O
antidepressants O
has O
been O
associated O
with O
the O
development O
of O
akathisia B-OSE_Labeled_AE
, O
characterized O
by O
a O
subjectively B-OSE_Labeled_AE
unpleasant I-OSE_Labeled_AE
or I-OSE_Labeled_AE
distressing I-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
and I-OSE_Labeled_AE
need I-OSE_Labeled_AE
to I-OSE_Labeled_AE
move I-OSE_Labeled_AE
, O
often O
accompanied O
by O
an O
inability B-OSE_Labeled_AE
to I-OSE_Labeled_AE
sit I-OSE_Labeled_AE
or I-OSE_Labeled_AE
stand I-OSE_Labeled_AE
still I-OSE_Labeled_AE
. O

This O
is O
most O
likely O
to O
occur O
within O
the O
first O
few O
weeks O
of O
treatment O
. O

In O
patients O
who O
develop O
these O
symptoms O
, O
increasing O
the O
dose O
may O
be O
detrimental O
. O

Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
has O
been O
reported O
very O
rarely O
with O
the O
use O
of O
mirtazapine O
. O

Caution O
should O
be O
exercised O
in O
patients O
at O
risk O
, O
such O
as O
elderly O
patients O
or O
patients O
concomitantly O
treated O
with O
medications O
known O
to O
cause O
hyponatremia B-NonOSE_AE
. O

Somnolence O
In O
US O
controlled O
studies O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
54 O
% O
of O
patients O
treated O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
, O
compared O
to O
18 O
% O
for O
placebo O
and O
60 O
% O
for O
amitriptyline O
. O

In O
these O
studies O
, O
somnolence B-OSE_Labeled_AE
resulted O
in O
discontinuation O
for O
10.4 O
% O
of O
REMERON-treated O
patients O
, O
compared O
to O
2.2 O
% O
for O
placebo O
. O

It O
is O
unclear O
whether O
or O
not O
tolerance O
develops O
to O
the O
somnolent O
effects O
of O
REMERON O
. O

Because O
of O
the O
potentially O
significant O
effects O
of O
REMERON O
on O
impairment B-NonOSE_AE
of I-NonOSE_AE
performance I-NonOSE_AE
, O
patients O
should O
be O
cautioned O
about O
engaging O
in O
activities O
requiring O
alertness O
until O
they O
have O
been O
able O
to O
assess O
the O
drug O
's O
effect O
on O
their O
own O
psychomotor O
performance O
( O
see O
PRECAUTIONS O
: O
Information O
for O
Patients O
) O
. O

Dizziness O
In O
US O
controlled O
studies O
, O
dizziness B-OSE_Labeled_AE
was O
reported O
in O
7 O
% O
of O
patients O
treated O
with O
REMERON O
, O
compared O
to O
3 O
% O
for O
placebo O
and O
14 O
% O
for O
amitriptyline O
. O

It O
is O
unclear O
whether O
or O
not O
tolerance O
develops O
to O
the O
dizziness B-NonOSE_AE
observed O
in O
association O
with O
the O
use O
of O
REMERON O
. O

Increased O
Appetite/Weight O
Gain O
In O
US O
controlled O
studies O
, O
appetite B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
was O
reported O
in O
17 O
% O
of O
patients O
treated O
with O
REMERON O
, O
compared O
to O
2 O
% O
for O
placebo O
and O
6 O
% O
for O
amitriptyline O
. O

In O
these O
same O
trials O
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
of I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was O
reported O
in O
7.5 O
% O
of O
patients O
treated O
with O
mirtazapine O
, O
compared O
to O
0 O
% O
for O
placebo O
and O
5.9 O
% O
for O
amitriptyline O
. O

In O
a O
pool O
of O
premarketing O
US O
studies O
, O
including O
many O
patients O
for O
long-term O
, O
open-label O
treatment O
, O
8 O
% O
of O
patients O
receiving O
REMERON O
discontinued O
for O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

In O
an O
8-week-long O
pediatric O
clinical O
trial O
of O
doses O
between O
15 O
to O
45 O
mg/day O
, O
49 O
% O
of O
REMERON-treated O
patients O
had O
a O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
of O
at O
least O
7 O
% O
, O
compared O
to O
5.7 O
% O
of O
placebo-treated O
patients O
( O
see O
PRECAUTIONS O
: O
Pediatric O
Use O
) O
. O

Cholesterol/Triglycerides O
In O
US O
controlled O
studies O
, O
nonfasting O
cholesterol B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
to O
> O
=20 O
% O
above O
the O
upper O
limits O
of O
normal O
were O
observed O
in O
15 O
% O
of O
patients O
treated O
with O
REMERON O
, O
compared O
to O
7 O
% O
for O
placebo O
and O
8 O
% O
for O
amitriptyline O
. O

In O
these O
same O
studies O
, O
nonfasting O
triglyceride B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
to O
> O
=500 O
mg/dL O
were O
observed O
in O
6 O
% O
of O
patients O
treated O
with O
mirtazapine O
, O
compared O
to O
3 O
% O
for O
placebo O
and O
3 O
% O
for O
amitriptyline O
. O

Transaminase B-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
Clinically O
significant O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
( O
> O
=3 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
were O
observed O
in O
2.0 O
% O
( O
8/424 O
) O
of O
patients O
exposed O
to O
REMERON O
in O
a O
pool O
of O
short-term O
US O
controlled O
trials O
, O
compared O
to O
0.3 O
% O
( O
1/328 O
) O
of O
placebo O
patients O
and O
2.0 O
% O
( O
3/181 O
) O
of O
amitriptyline O
patients O
. O

Most O
of O
these O
patients O
with O
ALT B-NonOSE_AE
increases I-NonOSE_AE
did O
not O
develop O
signs O
or O
symptoms O
associated O
with O
compromised B-NonOSE_AE
liver I-NonOSE_AE
function I-NonOSE_AE
. O

While O
some O
patients O
were O
discontinued O
for O
the O
ALT B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
, O
in O
other O
cases O
, O
the O
enzyme O
levels O
returned O
to O
normal O
despite O
continued O
REMERON O
treatment O
. O

REMERON O
should O
be O
used O
with O
caution O
in O
patients O
with O
impaired B-Not_AE_Candidate
hepatic I-Not_AE_Candidate
function I-Not_AE_Candidate
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Activation O
of O
Mania/Hypomania O
Mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
occurred O
in O
approximately O
0.2 O
% O
( O
3/1299 O
patients O
) O
of O
REMERON-treated O
patients O
in O
US O
studies O
. O

Although O
the O
incidence O
of O
mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
was O
very O
low O
during O
treatment O
with O
mirtazapine O
, O
it O
should O
be O
used O
carefully O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
/ O
hypomania B-Not_AE_Candidate
. O

Seizure O
In O
premarketing O
clinical O
trials O
, O
only O
1 O
seizure B-OSE_Labeled_AE
was O
reported O
among O
the O
2796 O
US O
and O
non-US O
patients O
treated O
with O
REMERON O
. O

However O
, O
no O
controlled O
studies O
have O
been O
carried O
out O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
. O

Therefore O
, O
care O
should O
be O
exercised O
when O
mirtazapine O
is O
used O
in O
these O
patients O
. O

Use O
in O
Patients O
with O
Concomitant O
Illness O
Clinical O
experience O
with O
REMERON O
in O
patients O
with O
concomitant O
systemic O
illness O
is O
limited O
. O

Accordingly O
, O
care O
is O
advisable O
in O
prescribing O
mirtazapine O
for O
patients O
with O
diseases O
or O
conditions O
that O
affect O
metabolism O
or O
hemodynamic O
responses O
. O

REMERON O
has O
not O
been O
systematically O
evaluated O
or O
used O
to O
any O
appreciable O
extent O
in O
patients O
with O
a O
recent O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
other O
significant O
heart B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

REMERON O
was O
associated O
with O
significant O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
in O
early O
clinical O
pharmacology O
trials O
with O
normal O
volunteers O
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
was O
infrequently O
observed O
in O
clinical O
trials O
with O
depressed B-Not_AE_Candidate
patients O
. O

REMERON O
should O
be O
used O
with O
caution O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
or O
cerebrovascular O
disease I-Not_AE_Candidate
that O
could O
be O
exacerbated O
by O
hypotension B-NonOSE_AE
( O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
angina B-Not_AE_Candidate
, O
or O
ischemic B-Not_AE_Candidate
stroke I-Not_AE_Candidate
) O
and O
conditions O
that O
would O
predispose O
patients O
to O
hypotension B-NonOSE_AE
( O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
and O
treatment O
with O
antihypertensive O
medication O
) O
. O

Mirtazapine O
clearance O
is O
decreased O
in O
patients O
with O
moderate O
[ O
glomerular B-Not_AE_Candidate
filtration I-Not_AE_Candidate
rate I-Not_AE_Candidate
( I-Not_AE_Candidate
GFR I-Not_AE_Candidate
) I-Not_AE_Candidate
= I-Not_AE_Candidate
1 I-Not_AE_Candidate
1 I-Not_AE_Candidate
- I-Not_AE_Candidate
3 I-Not_AE_Candidate
9 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
] O
and O
severe O
[ O
GFR B-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
] O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
and O
also O
in O
patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Caution O
is O
indicated O
in O
administering O
REMERON O
to O
such O
patients O
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Information O
for O
Patients O
Prescribers O
or O
other O
health O
professionals O
should O
inform O
patients O
, O
their O
families O
, O
and O
their O
caregivers O
about O
the O
benefits O
and O
risks O
associated O
with O
treatment O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
and O
should O
counsel O
them O
in O
its O
appropriate O
use O
. O

A O
patient O
Medication O
Guide O
about O
`` O
Antidepressant O
Medicines O
, O
Depression B-NonOSE_AE
and O
other O
Serious O
Mental B-NonOSE_AE
Illnesses I-NonOSE_AE
, O
and O
Suicidal B-NonOSE_AE
Thoughts O
or O
Actions I-NonOSE_AE
`` O
is O
available O
for O
REMERON O
. O

The O
prescriber O
or O
health O
professional O
should O
instruct O
patients O
, O
their O
families O
, O
and O
their O
caregivers O
to O
read O
the O
Medication O
Guide O
and O
should O
assist O
them O
in O
understanding O
its O
contents O
. O

Patients O
should O
be O
given O
the O
opportunity O
to O
discuss O
the O
contents O
of O
the O
Medication O
Guide O
and O
to O
obtain O
answers O
to O
any O
questions O
they O
may O
have O
. O

The O
complete O
text O
of O
the O
Medication O
Guide O
is O
reprinted O
at O
the O
end O
of O
this O
document O
. O

Patients O
should O
be O
advised O
of O
the O
following O
issues O
and O
asked O
to O
alert O
their O
prescriber O
if O
these O
occur O
while O
taking O
REMERON O
. O

Clinical O
Worsening O
and O
Suicide O
Risk O
Patients O
, O
their O
families O
, O
and O
their O
caregivers O
should O
be O
encouraged O
to O
be O
alert O
to O
the O
emergence O
of O
anxiety B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
panic B-NonOSE_AE
attacks I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
hostility B-NonOSE_AE
, O
aggressiveness B-NonOSE_AE
, O
impulsivity B-NonOSE_AE
, O
akathisia B-NonOSE_AE
( O
psychomotor B-NonOSE_AE
restlessness I-NonOSE_AE
) O
, O
hypomania B-NonOSE_AE
, O
mania B-NonOSE_AE
, O
other O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
and O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
, O
especially O
early O
during O
antidepressant O
treatment O
and O
when O
the O
dose O
is O
adjusted O
up O
or O
down O
. O

Families O
and O
caregivers O
of O
patients O
should O
be O
advised O
to O
look O
for O
the O
emergence O
of O
such O
symptoms O
on O
a O
day-to-day O
basis O
, O
since O
changes O
may O
be O
abrupt O
. O

Such O
symptoms O
should O
be O
reported O
to O
the O
patient O
's O
prescriber O
or O
health O
professional O
, O
especially O
if O
they O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Symptoms O
such O
as O
these O
may O
be O
associated O
with O
an O
increased O
risk O
for O
suicidal B-NonOSE_AE
thinking O
and O
behavior I-NonOSE_AE
and O
indicate O
a O
need O
for O
very O
close O
monitoring O
and O
possibly O
changes O
in O
the O
medication O
. O

Agranulocytosis O
Patients O
who O
are O
to O
receive O
REMERON O
should O
be O
warned O
about O
the O
risk O
of O
developing O
agranulocytosis B-NonOSE_AE
. O

Patients O
should O
be O
advised O
to O
contact O
their O
physician O
if O
they O
experience O
any O
indication O
of O
infection B-NonOSE_AE
such O
as O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
sore B-NonOSE_AE
throat I-NonOSE_AE
, O
mucous B-NonOSE_AE
membrane I-NonOSE_AE
ulceration I-NonOSE_AE
, O
or O
other O
possible O
signs O
of O
infection B-NonOSE_AE
. O

Particular O
attention O
should O
be O
paid O
to O
any O
flu-like O
complaints O
or O
other O
symptoms O
that O
might O
suggest O
infection B-NonOSE_AE
. O

Interference O
with O
Cognitive O
and O
Motor O
Performance O
REMERON O
may O
impair B-NonOSE_AE
judgment I-NonOSE_AE
, O
thinking O
, O
and O
particularly O
, O
motor O
skills O
, O
because O
of O
its O
prominent O
sedative B-NonOSE_AE
effect I-NonOSE_AE
. O

The O
drowsiness B-NonOSE_AE
associated O
with O
mirtazapine O
use O
may O
impair B-NonOSE_AE
a I-NonOSE_AE
patient I-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
ability I-NonOSE_AE
to I-NonOSE_AE
drive I-NonOSE_AE
, O
use O
machines O
, O
or O
perform O
tasks O
that O
require O
alertness O
. O

Thus O
, O
patients O
should O
be O
cautioned O
about O
engaging O
in O
hazardous O
activities O
until O
they O
are O
reasonably O
certain O
that O
REMERON O
therapy O
does O
not O
adversely B-NonOSE_AE
affect I-NonOSE_AE
their I-NonOSE_AE
ability I-NonOSE_AE
to I-NonOSE_AE
engage I-NonOSE_AE
in I-NonOSE_AE
such I-NonOSE_AE
activities I-NonOSE_AE
. O

Completing O
Course O
of O
Therapy O
While O
patients O
may O
notice O
improvement O
with O
REMERON O
therapy O
in O
1 O
to O
4 O
weeks O
, O
they O
should O
be O
advised O
to O
continue O
therapy O
as O
directed O
. O

Concomitant O
Medication O
Patients O
should O
be O
advised O
to O
inform O
their O
physician O
if O
they O
are O
taking O
, O
or O
intend O
to O
take O
, O
any O
prescription O
or O
over-the-counter O
drugs O
, O
since O
there O
is O
a O
potential O
for O
REMERON O
to O
interact O
with O
other O
drugs O
. O

Patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
if O
concomitant O
use O
of O
REMERON O
with O
other O
serotonergic O
drugs O
, O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
and O
St O
. O
John O
's O
wort O
, O
is O
clinically O
warranted O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Alcohol O
The O
impairment B-NonOSE_AE
of I-NonOSE_AE
cognitive O
and O
motor I-NonOSE_AE
skills I-NonOSE_AE
produced O
by O
REMERON O
has O
been O
shown O
to O
be O
additive O
with O
those O
produced O
by O
alcohol O
. O

Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol O
while O
taking O
mirtazapine O
. O

Pregnancy O
Patients O
should O
be O
advised O
to O
notify O
their O
physician O
if O
they O
become O
pregnant B-NonOSE_AE
or O
intend O
to O
become O
pregnant B-NonOSE_AE
during O
REMERON O
therapy O
. O

Nursing O
Patients O
should O
be O
advised O
to O
notify O
their O
physician O
if O
they O
are O
breastfeeding O
an O
infant O
. O

Laboratory O
Tests O
There O
are O
no O
routine O
laboratory O
tests O
recommended O
. O

Drug O
Interactions O
As O
with O
other O
drugs O
, O
the O
potential O
for O
interaction O
by O
a O
variety O
of O
mechanisms O
( O
e.g. O
, O
pharmacodynamic O
, O
pharmacokinetic O
inhibition O
or O
enhancement O
, O
etc O
. O
) O

is O
a O
possibility O
( O
see O
CLINICAL O
PHARMACOLOGY O
) O
. O

Monoamine O
Oxidase O
Inhibitors O
( O
See O
CONTRAINDICATIONS O
, O
WARNINGS O
, O
and O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

Serotonergic O
Drugs O
( O
See O
CONTRAINDICATIONS O
and O
WARNINGS O
. O
) O

Drugs O
Affecting O
Hepatic O
Metabolism O
The O
metabolism O
and O
pharmacokinetics O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
may O
be O
affected O
by O
the O
induction O
or O
inhibition O
of O
drug-metabolizing O
enzymes O
. O

Drugs O
that O
are O
Metabolized O
by O
and/or O
Inhibit O
Cytochrome O
P450 O
Enzymes O
CYP O
Enzyme O
Inducers O
( O
these O
studies O
used O
both O
drugs O
at O
steady O
state O
) O
Phenytoin O
In O
healthy O
male O
patients O
( O
n=18 O
) O
, O
phenytoin O
( O
200 O
mg O
daily O
) O
increased O
mirtazapine O
( O
30 O
mg O
daily O
) O
clearance O
about O
2-fold O
, O
resulting O
in O
a O
decrease O
in O
average O
plasma O
mirtazapine O
concentrations O
of O
45 O
% O
. O

Mirtazapine O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
phenytoin O
. O

Carbamazepine O
In O
healthy O
male O
patients O
( O
n=24 O
) O
, O
carbamazepine O
( O
400 O
mg O
b.i.d O
. O
) O

increased O
mirtazapine O
( O
15 O
mg O
b.i.d O
. O
) O

clearance O
about O
2-fold O
, O
resulting O
in O
a O
decrease O
in O
average O
plasma O
mirtazapine O
concentrations O
of O
60 O
% O
. O

When O
phenytoin O
, O
carbamazepine O
, O
or O
another O
inducer O
of O
hepatic O
metabolism O
( O
such O
as O
rifampicin O
) O
is O
added O
to O
mirtazapine O
therapy O
, O
the O
mirtazapine O
dose O
may O
have O
to O
be O
increased O
. O

If O
treatment O
with O
such O
a O
medicinal O
product O
is O
discontinued O
, O
it O
may O
be O
necessary O
to O
reduce O
the O
mirtazapine O
dose O
. O

CYP O
Enzyme O
Inhibitors O
Cimetidine O
In O
healthy O
male O
patients O
( O
n=12 O
) O
, O
when O
cimetidine O
, O
a O
weak O
inhibitor O
of O
CYP1A2 O
, O
CYP2D6 O
, O
and O
CYP3A4 O
, O
given O
at O
800 O
mg O
b.i.d O
. O

at O
steady O
state O
was O
coadministered O
with O
mirtazapine O
( O
30 O
mg O
daily O
) O
at O
steady O
state O
, O
the O
Area O
Under O
the O
Curve O
( O
AUC O
) O
of O
mirtazapine O
increased O
more O
than O
50 O
% O
. O

Mirtazapine O
did O
not O
cause O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
cimetidine O
. O

The O
mirtazapine O
dose O
may O
have O
to O
be O
decreased O
when O
concomitant O
treatment O
with O
cimetidine O
is O
started O
, O
or O
increased O
when O
cimetidine O
treatment O
is O
discontinued O
. O

Ketoconazole O
In O
healthy O
, O
male O
, O
Caucasian O
patients O
( O
n=24 O
) O
, O
coadministration O
of O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole O
( O
200 O
mg O
b.i.d O
. O

for O
6.5 O
days O
) O
increased O
the O
peak O
plasma O
levels O
and O
the O
AUC O
of O
a O
single O
30-mg O
dose O
of O
mirtazapine O
by O
approximately O
40 O
% O
and O
50 O
% O
, O
respectively O
. O

Caution O
should O
be O
exercised O
when O
coadministering O
mirtazapine O
with O
potent O
CYP3A4 O
inhibitors O
, O
HIV O
protease O
inhibitors O
, O
azole O
antifungals O
, O
erythromycin O
, O
or O
nefazodone O
. O

Paroxetine O
In O
an O
in O
vivo O
interaction O
study O
in O
healthy O
, O
CYP2D6 O
extensive O
metabolizer O
patients O
( O
n=24 O
) O
, O
mirtazapine O
( O
30 O
mg/day O
) O
, O
at O
steady O
state O
, O
did O
not O
cause O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
steady O
state O
paroxetine O
( O
40 O
mg/day O
) O
, O
a O
CYP2D6 O
inhibitor O
. O

Other O
Drug-Drug O
Interactions O
Amitriptyline O
In O
healthy O
, O
CYP2D6 O
extensive O
metabolizer O
patients O
( O
n=32 O
) O
, O
amitriptyline O
( O
75 O
mg O
daily O
) O
, O
at O
steady O
state O
, O
did O
not O
cause O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
steady O
state O
mirtazapine O
( O
30 O
mg O
daily O
) O
; O
mirtazapine O
also O
did O
not O
cause O
relevant O
changes O
to O
the O
pharmacokinetics O
of O
amitriptyline O
. O

Warfarin O
In O
healthy O
male O
subjects O
( O
n=16 O
) O
, O
mirtazapine O
( O
30 O
mg O
daily O
) O
, O
at O
steady O
state O
, O
caused O
a O
small O
( O
0.2 O
) O
but O
statistically O
significant O
increase B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
International I-NonOSE_AE
Normalized I-NonOSE_AE
Ratio I-NonOSE_AE
( I-NonOSE_AE
INR I-NonOSE_AE
) O
in O
subjects O
treated O
with O
warfarin O
. O

As O
at O
a O
higher O
dose O
of O
mirtazapine O
, O
a O
more O
pronounced O
effect O
can O
not O
be O
excluded O
, O
it O
is O
advisable O
to O
monitor O
the O
INR O
in O
case O
of O
concomitant O
treatment O
of O
warfarin O
with O
mirtazapine O
. O

Lithium O
No O
relevant O
clinical O
effects O
or O
significant O
changes O
in O
pharmacokinetics O
have O
been O
observed O
in O
healthy O
male O
subjects O
on O
concurrent O
treatment O
with O
subtherapeutic O
levels O
of O
lithium O
( O
600 O
mg/day O
for O
10 O
days O
) O
at O
steady O
state O
and O
a O
single O
30-mg O
dose O
of O
mirtazapine O
. O

The O
effects O
of O
higher O
doses O
of O
lithium O
on O
the O
pharmacokinetics O
of O
mirtazapine O
are O
unknown O
. O

Risperidone O
In O
an O
in O
vivo O
, O
nonrandomized O
, O
interaction O
study O
, O
subjects O
( O
n=6 O
) O
in O
need O
of O
treatment O
with O
an O
antipsychotic O
and O
antidepressant O
drug O
, O
showed O
that O
mirtazapine O
( O
30 O
mg O
daily O
) O
at O
steady O
state O
did O
not O
influence O
the O
pharmacokinetics O
of O
risperidone O
( O
up O
to O
3 O
mg O
b.i.d O
. O
) O
. O

Alcohol O
Concomitant O
administration O
of O
alcohol O
( O
equivalent O
to O
60 O
g O
) O
had O
a O
minimal O
effect O
on O
plasma O
levels O
of O
mirtazapine O
( O
15 O
mg O
) O
in O
6 O
healthy O
male O
subjects O
. O

However O
, O
the O
impairment B-NonOSE_AE
of I-NonOSE_AE
cognitive I-NonOSE_AE
and O
motor O
skills I-NonOSE_AE
produced O
by O
REMERON O
were O
shown O
to O
be O
additive O
with O
those O
produced O
by O
alcohol O
. O

Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol O
while O
taking O
REMERON O
. O

Diazepam O
Concomitant O
administration O
of O
diazepam O
( O
15 O
mg O
) O
had O
a O
minimal O
effect O
on O
plasma O
levels O
of O
mirtazapine O
( O
15 O
mg O
) O
in O
12 O
healthy O
subjects O
. O

However O
, O
the O
impairment B-NonOSE_AE
of I-NonOSE_AE
motor I-NonOSE_AE
skills I-NonOSE_AE
produced O
by O
REMERON O
has O
been O
shown O
to O
be O
additive O
with O
those O
caused O
by O
diazepam O
. O

Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
diazepam O
and O
other O
similar O
drugs O
while O
taking O
REMERON O
. O

QTc-Prolonging O
Drugs O
The O
risk O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
and/or O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
( O
e.g. O
, O
Torsades B-NonOSE_AE
de I-NonOSE_AE
Pointes I-NonOSE_AE
) O
may O
be O
increased O
with O
concomitant O
use O
of O
medicines O
which O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
( O
e.g. O
, O
some O
antipsychotics O
and O
antibiotics O
) O
and O
in O
case O
of O
mirtazapine O
overdose O
( O
see O
ADVERSE O
REACTIONS O
and O
OVERDOSE O
sections O
) O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Carcinogenesis O
Carcinogenicity B-NonOSE_AE
studies O
were O
conducted O
with O
mirtazapine O
given O
in O
the O
diet O
at O
doses O
of O
2 O
, O
20 O
, O
and O
200 O
mg/kg/day O
to O
mice O
and O
2 O
, O
20 O
, O
and O
60 O
mg/kg/day O
to O
rats O
. O

The O
highest O
doses O
used O
are O
approximately O
20 O
and O
12 O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
of O
45 O
mg/day O
on O
an O
mg/m O
2 O
basis O
in O
mice O
and O
rats O
, O
respectively O
. O

There O
was O
an O
increased O
incidence O
of O
hepatocellular B-NonOSE_AE
adenoma O
and O
carcinoma I-NonOSE_AE
in O
male O
mice O
at O
the O
high O
dose O
. O

In O
rats O
, O
there O
was O
an O
increase O
in O
hepatocellular B-NonOSE_AE
adenoma I-NonOSE_AE
in O
females O
at O
the O
mid O
and O
high O
doses O
and O
in O
hepatocellular B-NonOSE_AE
tumors I-NonOSE_AE
and O
thyroid B-NonOSE_AE
follicular I-NonOSE_AE
adenoma/cystadenoma O
and O
carcinoma I-NonOSE_AE
in O
males O
at O
the O
high O
dose O
. O

The O
data O
suggest O
that O
the O
above O
effects O
could O
possibly O
be O
mediated O
by O
non-genotoxic O
mechanisms O
, O
the O
relevance O
of O
which O
to O
humans O
is O
not O
known O
. O

The O
doses O
used O
in O
the O
mouse O
study O
may O
not O
have O
been O
high O
enough O
to O
fully O
characterize O
the O
carcinogenic B-NonOSE_AE
potential O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
. O

Mutagenesis O
Mirtazapine O
was O
not O
mutagenic B-NonOSE_AE
or O
clastogenic B-NonOSE_AE
and O
did O
not O
induce O
general O
DNA O
damage O
as O
determined O
in O
several O
genotoxicity B-NonOSE_AE
tests O
: O
Ames O
test O
, O
in O
vitro O
gene O
mutation O
assay O
in O
Chinese O
hamster O
V O
79 O
cells O
, O
in O
vitro O
sister O
chromatid O
exchange O
assay O
in O
cultured O
rabbit O
lymphocytes O
, O
in O
vivo O
bone O
marrow O
micronucleus O
test O
in O
rats O
, O
and O
unscheduled O
DNA O
synthesis O
assay O
in O
HeLa O
cells O
. O

Impairment B-NonOSE_AE
of I-NonOSE_AE
Fertility I-NonOSE_AE
In O
a O
fertility O
study O
in O
rats O
, O
mirtazapine O
was O
given O
at O
doses O
up O
to O
100 O
mg/kg O
[ O
20 O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
on O
an O
mg/m O
2 O
basis O
] O
. O

Mating O
and O
conception O
were O
not O
affected O
by O
the O
drug O
, O
but O
estrous O
cycling O
was O
disrupted O
at O
doses O
that O
were O
3 O
or O
more O
times O
the O
MRHD O
, O
and O
pre B-NonOSE_AE
- I-NonOSE_AE
implantation I-NonOSE_AE
losses I-NonOSE_AE
occurred O
at O
20 O
times O
the O
MRHD O
. O

Pregnancy O
Teratogenic O
Effects O
Pregnancy O
Category O
C O
Reproduction O
studies O
in O
pregnant B-NonOSE_AE
rats O
and O
rabbits O
at O
doses O
up O
to O
100 O
mg/kg O
and O
40 O
mg/kg O
, O
respectively O
[ O
20 O
and O
17 O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
on O
an O
mg/m O
2 O
basis O
, O
respectively O
] O
, O
have O
revealed O
no O
evidence O
of O
teratogenic B-NonOSE_AE
effects I-NonOSE_AE
. O

However O
, O
in O
rats O
, O
there O
was O
an O
increase O
in O
postimplantation B-NonOSE_AE
losses I-NonOSE_AE
in O
dams O
treated O
with O
mirtazapine O
. O

There O
was O
an O
increase O
in O
pup B-NonOSE_AE
deaths I-NonOSE_AE
during O
the O
first O
3 O
days O
of O
lactation O
and O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
pup I-NonOSE_AE
birth I-NonOSE_AE
weights I-NonOSE_AE
. O

The O
cause O
of O
these O
deaths B-NonOSE_AE
is O
not O
known O
. O

The O
effects O
occurred O
at O
doses O
that O
were O
20 O
times O
the O
MRHD O
, O
but O
not O
at O
3 O
times O
the O
MRHD O
, O
on O
an O
mg/m O
2 O
basis O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Because O
animal O
reproduction O
studies O
are O
not O
always O
predictive O
of O
human O
response O
, O
this O
drug O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
clearly O
needed O
. O

Nursing O
Mothers O
Because O
some O
REMERON O
may O
be O
excreted O
into O
breast O
milk O
, O
caution O
should O
be O
exercised O
when O
REMERON O
( O
mirtazapine O
) O
Tablets O
are O
administered O
to O
nursing O
women O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
in O
the O
pediatric O
population O
have O
not O
been O
established O
( O
see O
BOXED O
WARNING O
and O
WARNINGS O
: O
Clinical O
Worsening O
and O
Suicide O
Risk O
) O
. O

Two O
placebo-controlled O
trials O
in O
258 O
pediatric O
patients O
with O
MDD B-Not_AE_Candidate
have O
been O
conducted O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
, O
and O
the O
data O
were O
not O
sufficient O
to O
support O
a O
claim O
for O
use O
in O
pediatric O
patients O
. O

Anyone O
considering O
the O
use O
of O
REMERON O
in O
a O
child O
or O
adolescent O
must O
balance O
the O
potential O
risks O
with O
the O
clinical O
need O
. O

In O
an O
8-week-long O
pediatric O
clinical O
trial O
of O
doses O
between O
15 O
to O
45 O
mg/day O
, O
49 O
% O
of O
REMERON-treated O
patients O
had O
a O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
of O
at O
least O
7 O
% O
, O
compared O
to O
5.7 O
% O
of O
placebo-treated O
patients O
. O

The O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was O
4 O
kg O
( O
2 O
kg O
SD O
) O
for O
REMERON-treated O
patients O
versus O
1 O
kg O
( O
2 O
kg O
SD O
) O
for O
placebo-treated O
patients O
( O
see O
PRECAUTIONS O
: O
Increased B-NonOSE_AE
Appetite I-NonOSE_AE
/ O
Weight B-NonOSE_AE
Gain I-NonOSE_AE
) O
. O

Geriatric O
Use O
Approximately O
190 O
elderly O
individuals O
( O
> O
=65 O
years O
of O
age O
) O
participated O
in O
clinical O
studies O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
. O

This O
drug O
is O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
( O
75 O
% O
) O
, O
and O
the O
risk O
of O
decreased O
clearance O
of O
this O
drug O
is O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
care O
should O
be O
taken O
in O
dose O
selection O
. O

Sedating O
drugs O
may O
cause O
confusion B-NonOSE_AE
and O
over B-NonOSE_AE
- I-NonOSE_AE
sedation I-NonOSE_AE
in O
the O
elderly O
. O

No O
unusual O
adverse O
age-related O
phenomena O
were O
identified O
in O
this O
group O
. O

Pharmacokinetic O
studies O
revealed O
a O
decreased O
clearance O
in O
the O
elderly O
. O

Caution O
is O
indicated O
in O
administering O
REMERON O
to O
elderly O
patients O
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

